AKT inhibitor shows signs of effectiveness in a patient trial matching drugs to tumor gene mutations
New study updates evidence on rare blood-clotting condition after COVID-19 vaccination
26 October 2022Can gut bacteria cause rheumatoid arthritis?
27 October 2022AKT inhibitor shows signs of effectiveness in a patient trial matching drugs to tumor gene mutations
In a trial matching new treatments to cancer patients based on the genetic makeup of their tumors, the tumors shrank in 22% of the patients treated with the AKT inhibitor drug ipatasertib. This included patients with breast cancer and endometrial cancer as well as two rarer forms—anal and salivary gland. In the majority of the other patients (56%) their cancer remained stable, meaning their tumors neither shrank nor grew.
